CAT
Caterpillar Inc.
CAT's fundamentals are strong, but it looks expensive: trading at 24x earnings, above its usual 18x. Analysts expect strong earnings growth, though they disagree widely on how much.
UHAL-B
U-Haul Holding Company
There isn't enough reported data to score UHAL-B yet.
CAT Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Strong |
CAT's revenue, profitability, cash flow and balance sheet are all currently healthy.
UHAL-B Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Healthy | |
| Unavailable | |
| Under pressure |
UHAL-B's profitability is currently healthy, but its balance sheet is under pressure. There isn't enough data to rate its revenue and cash flow.
CAT PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 15x | $380 | -37% |
| Fair | 18x | $461 | -24% |
| Forward | 20x | $605 | — |
| Current | 24x | $605 | — |
| Expensive | 33x | $840 | +39% |
Historical ranges are pointers, not guarantees.
CAT's PE is in its expensive range at 24x. If earnings grow as analysts expect, today's price would be 20x next year's earnings, in its fair range.
UHAL-B PE Valuation
UHAL-B has no meaningful PE right now: it lost money over the past year.
CAT Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Moderate | |
| Low |
Analysts expect earnings and revenue growth for CAT, with profitability improving. However, they disagree widely on these estimates.
UHAL-B Forward outlook
There aren't enough analyst estimates for UHAL-B to show an outlook.
CAT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $30.32 | +19% |
| Q3 2026 | $25.48 | +31% |
| Q2 2026 | $23.23 | +18% |
| Q1 2026 | $20.08 | -2% |
| Q4 2025 | $18.81 | -15% |
| Q3 2025 | $19.46 | -9.7% |
| Q2 2025 | $19.64 | -10% |
| Q1 2025 | $20.50 | -7.4% |
| Q4 2024 | $22.05 | +9.6% |
CAT has the edge over UHAL-B in the latest year-over-year earnings comparison.
UHAL-B Earnings Per Share
UHAL-B's earnings per share have fallen from their peak: $1.00 over the past year, against $3.77 in late 2023.
CAT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $20.7B | +17% |
| Q2 2026 | $20.5B | +24% |
| Q1 2026 | $17.4B | +22% |
| Q4 2025 | $19.1B | +18% |
| Q3 2025 | $17.6B | +9.5% |
| Q2 2025 | $16.6B | -0.7% |
| Q1 2025 | $14.2B | -9.8% |
| Q4 2024 | $16.2B | -5% |
CAT has the stronger quarterly revenue trend. Revenue is up 17% for CAT versus up 8.7% for UHAL-B.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 20% | +3.1 points |
| Q2 2026 | 21% | +3.6 points |
| Q1 2026 | 18% | -0.4 points |
| Q4 2025 | 14% | -4.1 points |
| Q3 2025 | 17% | -2.2 points |
| Q2 2025 | 17% | -3.6 points |
| Q1 2025 | 18% | -4.2 points |
| Q4 2024 | 18% | -0.3 points |
CAT has the edge over UHAL-B on profitability, with a higher operating margin.
UHAL-B Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.8B | +3.1% |
| Q2 2026 | $1.7B | +3.2% |
| Q1 2026 | $1.3B | +3.1% |
| Q3 2025 | $1.7B | +3.7% |
| Q2 2025 | $1.6B | +5.3% |
| Q4 2024 | $1.4B | +3.7% |
| Q3 2024 | $1.7B | +0.5% |
| Q2 2024 | $1.5B | +0.5% |
UHAL-B's revenue has picked up after three years of holding roughly level: $1.8B last quarter, up 8.7% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 15% | -0.2 points |
| Q2 2026 | 15% | -2.1 points |
| Q1 2026 | -6% | -2.5 points |
| Q3 2025 | 15% | -3.1 points |
| Q2 2025 | 17% | -2.8 points |
| Q1 2025 | -3.5% | N/A |
| Q4 2024 | 11% | -3.9 points |
| Q3 2024 | 18% | -7.4 points |
UHAL-B's operating margin was 15% last quarter, down 2.1 points from the same quarter a year ago.
CAT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $3.7B | +19% |
| Q2 2026 | $3.8B | +47% |
| Q1 2026 | $1.1B | +97% |
| Q4 2025 | $2.7B | +0.1% |
| Q3 2025 | $3.1B | -1.5% |
| Q2 2025 | $2.6B | -4.2% |
| Q1 2025 | $579M | -63% |
| Q4 2024 | $2.7B | -22% |
CAT has the stronger cash trend. Its trailing FCF is up 39% versus its history, compared with UHAL-B at down 19%.
UHAL-B Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$342.7M | +$103.7M |
| Q2 2026 | -$192.1M | +$126.1M |
| Q1 2026 | -$147.7M | +$242.8M |
| Q3 2025 | -$446.3M | -$12.8M |
| Q2 2025 | -$318.2M | +$191.1M |
| Q4 2024 | -$664.9M | -$230.9M |
| Q3 2024 | -$433.5M | -$14.4M |
| Q2 2024 | -$509.3M | -$201.4M |
UHAL-B has burned cash in most quarters: −$1.1B over the past year, against −$1.8B the year before.
CAT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -1.6M shares |
| 1 year | -2.1% | -9.9M shares |
| 3 years | -10% | -51.7M shares |
| 5 years | -16% | -86.7M shares |
| Available history | -19% | -107M shares |
CAT has the edge over UHAL-B on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $1.2B |
| Q2 2026 | $1.5B |
| Q1 2026 | $5B |
| Q4 2025 | $340M |
| Q3 2025 | $362M |
| Q2 2025 | $828M |
| Q1 2025 | $3.7B |
| Q4 2024 | $640M |
CAT spent $8.1B buying back its own shares over the past year, up 47% from the year before.
UHAL-B Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.7% | -1.5M shares |
| 1 year | -0.9% | -1.7M shares |
| 3 years | -0.9% | -1.7M shares |
UHAL-B has 194M diluted shares, down 0.9% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $10.2M |
| Q2 2026 | $15.6M |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
CAT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.5x | Net Cash |
| Q2 2026 | -0.4x | Net Cash |
| Q1 2026 | -0.3x | Net Cash |
| Q4 2025 | 2.0x | Healthy |
| Q3 2025 | -0.6x | Net Cash |
| Q2 2025 | -0.4x | Net Cash |
| Q1 2025 | -0.3x | Net Cash |
| Q4 2024 | 1.6x | Healthy |
CAT has more cash than debt.
UHAL-B Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2025 | 3.9x | Elevated |
| Q2 2025 | 3.7x | Elevated |
| Q1 2025 | 3.6x | Elevated |
| Q4 2023 | 2.4x | Moderate |
| Q3 2023 | 2.1x | Moderate |
| Q2 2023 | 1.9x | Healthy |
| Q1 2023 | 1.9x | Healthy |
| Q4 2022 | 2.0x | Healthy |
UHAL-B's net debt is about 3.9 years of its operating earnings (EBITDA), up from 2.1 years a year ago.
CAT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.7 | Neutral |
| Stochastic | 6.7 | Oversold |
CAT's weekly RSI is 33 (neutral) and its Stochastic is 7 (oversold).
UHAL-B Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 39.1 | Neutral |
| Stochastic | 9.6 | Oversold |
UHAL-B's weekly RSI is 39 (neutral) and its Stochastic is 10 (oversold).
CAT PE vs Industrials Sector
| Metric | CAT | Sector median | Relative |
|---|---|---|---|
| PE | 24x | 24x | 1.3% below |
| PE % | 69 | 58 | 11 pts above |
CAT is trading at 24x earnings, in line with the Industrials sector's median of 24x.
UHAL-B PE vs Industrials Sector
| Metric | UHAL-B | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 24x | — |
UHAL-B has no meaningful PE right now: it lost money over the past year.
CAT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $709.0 | 15% below |
| 20 week MA | $797.0 | 24% below |
| 50 week MA | $771.3 | 22% below |
| 100 week MA | $586.7 | 3.2% above |
| 200 week MA | $443.1 | 37% above |
CAT has the edge over UHAL-B on trend strength, trading above more of its moving averages.
UHAL-B Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $51.1 | 3.5% below |
| 20 week MA | $57.0 | 14% below |
| 50 week MA | $51.9 | 5.2% below |
| 100 week MA | $54.0 | 8.8% below |
| 200 week MA | $56.8 | 13% below |
UHAL-B is in a downtrend: it's below all five of its weekly moving averages, and 13% below its 200-week average.
CAT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $148.3 | $179.6 | +21% |
| 2021 | $179.6 | $206.2 | +15% |
| 2022 | $206.2 | $239.9 | +16% |
| 2023 | $239.9 | $295.7 | +23% |
| 2024 | $295.7 | $364.9 | +23% |
| 2025 | $364.9 | $583.0 | +60% |
| 2026 YTD | $583.0 | $605.3 | +3.8% |
CAT has the edge over UHAL-B on returns for 2026, with the stronger performance.
UHAL-B Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2022 | $55.9 | $54.9 | -1.9% |
| 2023 | $54.9 | $70.4 | +28% |
| 2024 | $70.4 | $64.2 | -8.9% |
| 2025 | $64.2 | $47.6 | -26% |
| 2026 YTD | $47.6 | $49.3 | +3.4% |
UHAL-B has finished lower in three of the last four years. It's up 3.4% so far in 2026.